165 Apremilast, an oral phosphodiesterase-4 inhibitor, is associated with long-term (156-week) improvements in Bath Ankylosing Spondylitis Disease Activity Index Score in subjects with psoriatic arthritis: pooled results from three phase III randomised controlled trials. (25th April 2018) - Mease, Philip J; Marzo-Ortega, Helena; Poder, Airi; Van den Bosch, Filip; Wollenhaupt, Jurgen; Lespessailles, Eric; Teng, Lichen; Hall, Stephen